Semaglutide (Ozempic/Wegovy) has the strongest cardiovascular safety data of any weight loss drug
These experiments help clarify how integrated incretin and glucagon signaling affects the relationship between intake-side regulation and expenditure-side regulation in complex biological systems [1][5]
Retatrutide's glucagon receptor activity also introduces additional considerations around potential effects on heart rate and liver metabolism, which are being carefully monitored in ongoing research
GLP-1 RAs, however, work to suppress glucagon secretion to reduce blood glucose levels
Recovery time, surgical complications, and lifelong vitamin supplementation requirements factor into this decision
Brand-name Wegovy comes in pre-filled pens at fixed doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg)